Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Countries Urged To Open Up On Managed Entry Deals

Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.

International Comparative Effectiveness

The Netherlands Swaps Germany For Norway To Set Prices

The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices. 

Europe Netherlands

Luxembourg To Establish New Medicines Agency

Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.

Europe Luxembourg

Brazilian Regulator Sets New Drug Registration Records

Better dialogue with companies, together with new regulations and ways of working, have helped Brazil’s medicines regulator set new records for registering pharmaceuticals.

EU System ‘Not Perfect But Is Fit For Purpose’, Says EMA

The European Medicines Agency has rejected claims that industry fees and allegedly flawed methods of evaluating medicines can lead to problematic development and interpretation of evidence.

Europe Policy

USCMA Revision Worsens Innovator Woes In Canada

Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.
North America Canada
See All
UsernamePublicRestriction

Register